Beruflich Dokumente
Kultur Dokumente
2006
(32)
Askandar Tjokroprawiro
PLETAAL SYMPOSIUM
Integrated Clinical Management of Pts at High Risk of Vascular Events
Surabaya, 5 November 2006
ASK-DNC
2
Atherothrombosis : the Coupling of Atherosclerosis and Thromboembolim
an Event in All-Vascular Bed Disease
(Summarized : Tjokroprawiro 2006)
The Independent Risk Factors for the First Time Stroke Patients
(as Observed in Australia 2002)
1 Previous TIA (OR = 6.3)
2 Intermittent Claudication = IC (OR = 2.6)
3 Previous MI (OR = 1.9)
ASK-DNC
3
Hiatt (2001) Interpretation of ABI
Higher Right-Ankle Pressure Provided : 2006*
Right ABI > 1.30 Noncompressible
Higher Arm Pressure
0.91-1.30 Normal
Higher Right-Ankle Pressure
Left ABI 0.41-0.90 Mild-to-Moderate PAD
Higher Arm Pressure
1 0.00-0.40 Severe PAD
Physical Examination* 1 Neck
1 2 3 4 5 6 7 2 Flank
3 Abdomen
4 Groin
5 Popliteal Pulse
2
6 Tibial Pulse
Right-Arm 3 Left-Arm 7 Dorsal Pulse
Systolic Pressure Systolic Pressure
4
DP DP
Right-Ankle 6 Left-Ankle
Systolic Pressure PT PT Systolic Pressure
7
ASK-DNC
4
ABI TBI
(Ankle Brachial Index) (Toe Brachial Index)
Summarized : Tjokroprawiro 2000, 2001, 2003 , 2004 , 2006
IC : 0.6 up to 0.9 IC and Rest Pain : > 0.5 up to < 0.6 Rest Pain < 0.5
Moderate Intermediate Severe
ASK-DNC
5
Classification of PAD: Fontaine's Stages
(Fontaine 1954, ESC 2001*)
STAGE Characteristics %
I Asymptomatic 67%
(Strenuous Exercise : Leg Pain)
IIa Mild Claudication (WD > 200 m)
IIb Moderate-Severe Claudication
(WD < 200 m)
III Critical Limb Ischemia* 33%
Ischemic Pain at Rest
Pain at Rest and Skin Ulcer or Gangrene
IV Wagner 1983
Prevalence of Fontaine-IV GRADE : 1 -5
Diabetic Out-Patients in Surabaya : 3.8%
ASK-DNC
6
Classification of PAD
Rutherford's Categories: TASC, 2000
Trans Atlantic Inter-Society Consensus
Grade Category Clinical Description
0 0 Asymptomatic
1 1 Mild Claudication
1 2 Moderate Claudication
1 3 Severe Claudication
II 4 Ischemic Rest Pain
III 5 Minor Tissue Loss Wagner 1983
III 6 Major Tissue Loss GRADE : 1 -5
FONTAINE RUTHERFORD
Stage Clinical Grade Category Clinical
I Asymptomatic 0 0 Asymptomatic
IIa Mild Claudication I 1 Mild Claudication
IIb Moderate-severe Claudiation I 2 Moderate Claudication
I 3 Severe Claudication
III Ischemic Rest Pain II 4 Ischemic Rest Pain
IV Ulceration or Gangrene III 5 Minor Tissue Loss
IV 6 Ulceration or Gangrene
ASK-DNC
8
Major Clinical Manifestations of Atherothrombosis
The 10th European Stroke Conference
(Lisbon, 16-19 May 2001; Summarized : Tjokroprawiro 2002, 2006)
EarlyPractical
Early PracticalDiagnosis
Diagnosisof of PAD ::ABI
POAD ABI<<0.9; Suspected: :<<0.9-1.0
0.9; Suspected 0.9-1.0
(Ankle Brachial Index)
TBI : Toe Brachial Index
ASK-DNC
9
Classification of Recommendations and Level of Evidence
(ACC / AHA - 2006)
Condition for which there is evidence for and/or general agreement that
Class I
a given procedure or treatment is beneficial, useful, and effective
Condition for which there is conflicting evidence and/or divergence of
opinion about the usefulness/efficacy of a procedure or treatment
Class II
Class IIa : weight of evidence/opinion is in favour of usefulness/efficacy
Class IIb : usefulness/efficacy is less well established by evidence/opinion
Condition for which there is evidence and/or general agreement that a
Class III procedure/treatment is not useful/effective and in some cases may be
harmful
Level of Evidence A : Data derived from multiple randomized clinical
trials of meta-analyses
Level of Level of Evidence B : Data derived from a single randomized trial or
Evidence non-randomized studies
Level of Evidence C : Only consensus opinion of experts, case studies,
or standard-of-care
ASK-DNC
10
Antithrombotic Agents
(Doggrell, 2001; Hirsh, 2001; Summarized: Tjokroprawiro, 2003, 2006)
ASK-DNC
11
Anti Platelet Agents = APAs
(Summarized : Tjokroprawiro 1995, 1997, 1998, 1999, 2000, 2004, 2006)
ASK-DNC
12
Major Clinical Manifestations of Atherothrombosis
The 10th European Stroke Conference
(Lisbon, 16-19 May 2001; Summarized : Tjokroprawiro 2002, 2006)
EarlyPractical
Early PracticalDiagnosis
Diagnosisof of PAD ::ABI
POAD ABI<<0.9; Suspected: :<<0.9-1.0
0.9; Suspected 0.9-1.0
(Ankle Brachial Index)
TBI : Toe Brachial Index
ASK-DNC
13
Peripheral Arterial Disease (PAD)
All-Causes Mortality
(Criqui, 2001)
100
Normal Subjects
0.75
Survival
0.00
0 2 4 6 8 10 12 Year
* Kaplan-Meier survival curves based on mortality from all causes
Large-vessel PAD
ASK-DNC
14
Atherothrombosis-the Underlying Disease
Leading to Ischaemic Events
(Criqui, 2001)
Common Underlying
Atherothrombotic Disease Process
Atherothrombotic Events
MI, STROKE, or CV DEATH
ASK-DNC
15
Antithrombotic Trialists' Collaboration
(Bertrand et al 2000, Braunwald et al 2000, ATC 2002)
(Summarized : Tjokroprawiro 2006)
Recommendation :
- All Patients with IC or who have had previous vascular intervention
should be considered for long-term anti-platelet therapy (A).
Acute MI
Acute Stroke
Prior MI
Prior Stroke / TIA
Other High Risk*
25% + 3
All Trials (p<0.0001)
* Coronary Artery Disease, Peripheral Arterial Disease, High Risk of Embolism and Other
High Risk Conditions (including Hemodialysis, Diabetes Mellitus, Carotid Disease)
ASK-DNC
18
Antithrombotic Trialists' Collaboration : ATC-2002
Reduced Non-Fatal Myocardial Infarction
CATEGORY % ODDS REDUCTION
Acute MI
Prior MI
Prior Stroke / TIA
Other High Risk*
* Coronary Artery Disease, Peripheral Arterial Disease, High Risk of Embolism and Other
High Risk Conditions (including Hemodialysis, Diabetes Mellitus, Carotid Disease)
ASK-DNC
19
Antithrombotic Trialists' Collaboration : ATC-2002
Reduced Vascular Death Risk
CATEGORY % ODDS REDUCTION
Acute MI
Acute Stroke
Prior MI
Prior Stroke / TIA
Other High Risk*
15% + 2
All Trials (p<0.0001)
* Coronary Artery Disease, Peripheral Arterial Disease, High Risk of Embolism and Other
High Risk Conditions (including Hemodialysis, Diabetes Mellitus, Carotid Disease)
ASK-DNC
20
(Summarized : 2006)
ASK-DNC
21
Cilostazol : Quadruple Properties with Pleiotropic Benefits
(Summarized : Tjokroprawiro 2003-2006)
Degradation Products
G1 AC Gs
cAMP PKA
PDE3A-I (CS)
5'AMP Protein ~ P
ADENOSINE
ASK-DNC
23
Vascular SMC
A2 CS
A1 Gs AC
G1 cAMP AMP
AC
PKA
Selectivity
Relaxation
cAMP AMP
Adenosine
PKA PDE3 A2 CS
Contractility Gs AC
Arrhythmia cAMP AMP
PKA
Cardiacmyocyte Inhibition
CS Platelet
Aggregation
Fibrinogen
1.8
1.6
*
1.4 With and without CS (p<0.01)
CIMT (mm)
1.2 **
1 Before and after CS (p<0.001)
0.8
0.6
ASK-DNC
27
mg/dL CS 100mg BID (n=95)
200
Placebo (n=94)
Plasma TG
180
160
p<0.001
140
120
100
0 2 4 6 8 10 12 Week
50
48
46
44
p<0.001
42
40
38
0 2 4 6 8 10 12 Week
30 29.4 %
: CS
25 : Control
20
15
10
5
0%
0
CS 50-100 mg BID (n=28) Control (n=34)
0/28 10/34
(BT)
(BT)
: p<0.01
** : p<0.05
400 *
Paired t-test
20
200 10
(Sec) 0 (Sec) 0
Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post
Ticlopidine CS Aspirin Ticlopidine CS Aspirin
300 mg/day 200 mg/day 330 mg/day 300 mg/day 200 mg/day 330 mg/day
ISCHEMIC
SYMPTOMS
TG
HDL OF PAD
Intimal Hyperplasia
FR-Scavenging Activity Erythrocyte Deformability
ATHEROSCLEROSIS HAEMORRHEOLOGY
ASK-DNC
31
Placebo (n=226)
40
30
20
10
P<0.05 at all time points
0
0 4 8 12 16 20 24
Weeks of Treatment
MWD= maximum Walking Distance
ASK-DNC
32
PletaalTM 349.9 m
14.0 Pentoxifylline
307.9 m
10.5
Percent Grade
Placebo
(29% Greater
299.6 m
Intensity)
7.0
4.5 METs
3.5
3.5 METs
Mean MWD at 24
0.0
Weeks
0 3 6 9 12 16
Minutes
MET=Metabolic Equivalent
1 MET = 3.5 mL O2/kg/min
ASK-DNC
33
Treadmill and/or :
Initial Evaluation :
- SF-36 Questionnaire
- Hemoglobin
- WIQ Questionnaire
- Serum Creatinine
- Smoking history
- Lipid Profile Mild Symptoms Moderate Symptoms Severe Symptoms
- Hypertension Not Disabled Disabled Disabled
- Diabetes
Encourage Supervised Walking Exercise Program
Special Investigation : Consider Pharmacotherapy (PletaalTM)
- Hypercoagulation Screen
- Homocysteine Level
- Lp (a) Continue Successful Outcome Unsuccessful Outcome
- Other
ASK-DNC
34
Confirmed PAD Dx and Tx of Claudication (ACC/AHA-2006)
ASK-DNC
35
HYPERTENSION-DIABETES MELLITUS
LIPID-CIGARETTE
Symptomatic : 33%
Capillary Bed
Intermittent Claudication
"HDL-C Ischemia Permanent Critical Ischemia
PAD
Syndrome"
Asymptomatic : 67%
Reperfusion of Ischemic Tissue
Oxidative Stress Free Redicals
Lipid Peroxidation : Accumulation of
Metabolic Intermediates such as Acyl- Increased Acylcarnitines
carnitines, Synthesis of Phospho- Correlated with Decreased
creatine, & ADP Abundance of these Atherosclerotic Process Treadmill Exercise Performance
Compounds Metabolic Myopathy
ASK-DNC
36
Principles of Pathogenesis and Treatment of PAD and/or IC
(Clinical Experiences - Summarized : Tjokroprawiro 2001, 2003, 2004, 2006)
HYPERTENSION-DIABETES MELLITUS
LIPID-CIGARETTE Symptomatic : 33%
Intermittent Claudication
Capillary Bed Permanent Critical Ischemia
"HDL-C Ischemia Minor/Major Tissue Loss
PAD
Syndrome"
Asymptomatic : 67%
Medical Treatment : TLC and MNT
Diets : Diet KV or Diet G
FDA-approved 1999 Not Yet FDA-Approved
H : T < 130/80 mmHg
PLETAAL TM Buflomedil
D : Pre Prandial : 80-130 mg/dl
Peak PP < 180 mg/dl, AIC : 6-7% ACC/AHA-2006 Naftidrofuryl
Class-I &d Level of Evidence A Levocarnitine
L : LDL < 100 mg/dl or < 70 mg/dl
HDL-C > 40 mg/dl (Men)
Cilostazol-Pletaal Propionyl - L-Carnitine
HDL-C > 50 mg/dl (Women) Prostaglandins
Quadruple Properties PKC-Inhibitors
C : Stop Smoking
Pleiotropic
PHYSICAL EXERCISE Clinical Benefits
ASK-DNC
37
Medical andACC/AHA-2006
Pharmacological Treatmentand
: Guidelines for Claudication
Recommendations
CILOSTAZOL
(PLETAALTM)
Class I
1 PletaalTM 100 mg bid is an Effective Therapy to Improve
Symptoms and Increase WD in Lower Extremity PAD and IC
(in the absence of heart failure) : A
2 A Therapeutic Trial of PletaalTM should be considered in
All Patients with Lifestyle-limiting Claudication
(in the absence of heart failure) : A
ASK-DNC
38
Medical andACC/AHA-2006
Pharmacological Treatmentand
: Guidelines for Claudication
Recommendations
ASK-DNC
39
Hypothetical Scheme for the Mode of Action of Cilostazol
(Schrör, 2002)
Degradation Products
G1 AC Gs
cAMP PKA
PDE3A-I (CS)
5'AMP Protein ~ P
ADENOSINE
ASK-DNC
40
CILOSTAZOL : Dose 50-100 mg bid
(Summarized : Tjokroprawiro 2003)
ASK-DNC
42
Rio de Janeiro - Copacabana Beach
ASK-DNC